<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01047553</url>
  </required_header>
  <id_info>
    <org_study_id>D5122C00002</org_study_id>
    <nct_id>NCT01047553</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Formoterol in a Daily Dose of 18 µg (9 µg Twice Daily) in Japanese Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>An Open Phase III, Multi-centre 52-week, Parallel-group Study Evaluating the Safety and Efficacy of Formoterol 18 μg Daily Dose Compared With Standard COPD Treatment, in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicentre, open, randomised, parallel-group study with formoterol 9 μg one
      inhalation b.i.d, or standard COPD therapy. Standard (reference) COPD treatment arm should be
      the group to refer to when safety results of formoterol arm will be evaluated. 240 patients
      with moderate-to-severe COPD will be randomised (120 patients in the formoterol-arm and 120
      patients on standard COPD therapy).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Erythrocytes</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Mean change from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Haemoglobin</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology-Leucocytes</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology-Platelet Count</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology Eosinophils</measure>
    <time_frame>baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology Basophil</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology-Lymphocytes</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology-Monocytes</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Haematology -Neutrophils</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S-Creatinine</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S-Sodium</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S-Potassium</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S- Calcium</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S-Albumin</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry-S-Total Protein</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs- Sitting SBP</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs- Sitting DBP</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs - Pulse Rate</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables - Heart Rate</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables - QT Interval</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables - QTcB Interval</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables QTcF Interval</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG Variables RR Interval</measure>
    <time_frame>Baseline and week 52</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization</time_frame>
    <description>The ratio of the average value of available data for mean from Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization</time_frame>
    <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow(PEF)</measure>
    <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit)and daily during 52-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening Peak Expiratory Flow (PEF)</measure>
    <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</measure>
    <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
    <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</measure>
    <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
    <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</measure>
    <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment</time_frame>
    <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score</measure>
    <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
    <description>The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD Exacerbations Over the Treatment Period</measure>
    <time_frame>Daily during 52-week randomization treatment</time_frame>
    <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment was presented here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of SABA (Salbutamol) as Reliever Medication</measure>
    <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
    <description>The change from Run-in period average to Treatment period average for each treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire (SGRQ) Total Score</measure>
    <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
    <description>SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). The change from Run-in period average to Treatment period average for each treatment group</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">251</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol 9 μg/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol (OT)</intervention_name>
    <description>9 μg/dose, Inhaled, twice daily for 52 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Oxis Turbuhaler®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients, men or women ≥ 40 years

          -  A clinical diagnosis of COPD according to guidelines, and current COPD symptoms.

          -  Post-bronchodilator FEV1 &lt; 80% of predicted normal value and FEV1/FVC &lt; 70%,
             post-bronchodilator

        Exclusion Criteria:

          -  A history and/or current clinical diagnosis of asthma and atopic diseases such as
             Allergic rhinitis

          -  Patients who have experienced COPD exacerbation requiring at least one of the
             following treatment, hospitalisation and/or a course of systemic steroid within 4
             weeks prior to the study start.

          -  Significant or unstable ischaemic heart disease, arrhythmia, cardiomyopathy, heart
             failure, uncontrolled hypertension as defined by the investigator, or any other
             relevant cardiovascular disorder as judged by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Akita-shi</city>
        <state>Akita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>AKO</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hitachi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujisawa</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Koshi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagaoka</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saiki-shi</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katsushika-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tosima-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <results_first_submitted>July 18, 2012</results_first_submitted>
  <results_first_submitted_qc>December 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 4, 2013</results_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Japanese</keyword>
  <keyword>Phase 3</keyword>
  <keyword>Safety</keyword>
  <keyword>OT</keyword>
  <keyword>Oxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant entered the study on 18 December 2009, and the last participant completed the study on 20 July 2011. A total of 320 participants were enrolled at 30 centers in Japan, and 251 participants who fulfilled the randomization criteria were randomized.</recruitment_details>
      <pre_assignment_details>The study started with an enrolment visit, Visit 1, 1 week prior to Visit 2, and 1 week run-in period before randomization. At Visit 2 participants had to have pre-bronchodilatory forced expiratory volume in one second (FEV1) less than 80 percent of the predicted normal value.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Formoterol</title>
          <description>Formoterol 9 μg twice daily</description>
        </group>
        <group group_id="P2">
          <title>Standard Treatment</title>
          <description>Standard COPD (JRS guideline and GOLD) treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Development of Study-Specific Withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sever Non-Compliance to Protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>PI's decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Formoterol</title>
          <description>Formoterol 9 μg twice daily</description>
        </group>
        <group group_id="B2">
          <title>Standard Treatment</title>
          <description>Standard COPD (JRS guideline and GOLD) treatment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="126"/>
            <count group_id="B3" value="251"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.8" lower_limit="43" upper_limit="88"/>
                    <measurement group_id="B2" value="70.3" lower_limit="50" upper_limit="83"/>
                    <measurement group_id="B3" value="70.6" lower_limit="43" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Erythrocytes</title>
        <description>Mean change from Baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Erythrocytes</title>
          <description>Mean change from Baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>erythrocytes counts x10000/μl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.25" spread="23.8"/>
                    <measurement group_id="O2" value="-5.2" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Haemoglobin</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Haemoglobin</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.73"/>
                    <measurement group_id="O2" value="-0.20" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology-Leucocytes</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology-Leucocytes</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>leukocyte count/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-132.1" spread="1535.3"/>
                    <measurement group_id="O2" value="-289.5" spread="1284.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology-Platelet Count</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology-Platelet Count</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>Platelet Count x10000/μl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="3.29"/>
                    <measurement group_id="O2" value="-0.40" spread="4.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology Eosinophils</title>
        <description>Change from baseline</description>
        <time_frame>baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology Eosinophils</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>percentage of Eosinophil</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="2.21"/>
                    <measurement group_id="O2" value="0.45" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology Basophil</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology Basophil</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>percentage of Basophil</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.37"/>
                    <measurement group_id="O2" value="0.01" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology-Lymphocytes</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology-Lymphocytes</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>percentage of Lymphocyte</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="7.86"/>
                    <measurement group_id="O2" value="-0.43" spread="7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology-Monocytes</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology-Monocytes</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>percentage of Monocyte</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="1.55"/>
                    <measurement group_id="O2" value="-0.03" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Haematology -Neutrophils</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Haematology -Neutrophils</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>percentage of Neutrophil</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="8.32"/>
                    <measurement group_id="O2" value="-0.28" spread="7.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry- S-Alanine Aminotransferase</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>U/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="10.0"/>
                    <measurement group_id="O2" value="4.9" spread="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S-Aspartate Aminotransferase</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>U/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="12.0"/>
                    <measurement group_id="O2" value="2.6" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S-Alkaline Phosphatase (ALP)</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>U/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="44.7"/>
                    <measurement group_id="O2" value="-4.4" spread="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S-Creatinine</title>
        <description>Change from Baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S-Creatinine</title>
          <description>Change from Baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.009" spread="0.089"/>
                    <measurement group_id="O2" value="0.021" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S-Total Bilirubin</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.22"/>
                    <measurement group_id="O2" value="0.02" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S-Sodium</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S-Sodium</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>mEq/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.9"/>
                    <measurement group_id="O2" value="-0.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S-Potassium</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S-Potassium</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>mEq/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.34"/>
                    <measurement group_id="O2" value="-0.07" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S- Calcium</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S- Calcium</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.42"/>
                    <measurement group_id="O2" value="-0.03" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S-Albumin</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S-Albumin</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.28"/>
                    <measurement group_id="O2" value="0.00" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry-S-Total Protein</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry-S-Total Protein</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="0.40"/>
                    <measurement group_id="O2" value="-0.09" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Laboratory Test: Clinical Chemistry - S-Blood Urea Nitrogen (BUN)</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="4.00"/>
                    <measurement group_id="O2" value="0.07" spread="3.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs- Sitting SBP</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs- Sitting SBP</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="14.8"/>
                    <measurement group_id="O2" value="-2.1" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs- Sitting DBP</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs- Sitting DBP</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="8.9"/>
                    <measurement group_id="O2" value="-3.5" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vital Signs - Pulse Rate</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs - Pulse Rate</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>beats/minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="10.7"/>
                    <measurement group_id="O2" value="-0.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables - Heart Rate</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables - Heart Rate</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="11.4"/>
                    <measurement group_id="O2" value="0.6" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables - QT Interval</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables - QT Interval</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>milisecond</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="22.8"/>
                    <measurement group_id="O2" value="2.6" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables - QTcB Interval</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables - QTcB Interval</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>milisecond</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="20.6"/>
                    <measurement group_id="O2" value="1.2" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables QTcF Interval</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables QTcF Interval</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>milisecond</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="15.1"/>
                    <measurement group_id="O2" value="1.7" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ECG Variables RR Interval</title>
        <description>Change from baseline</description>
        <time_frame>Baseline and week 52</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>ECG Variables RR Interval</title>
          <description>Change from baseline</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any safety data after randomisation were available were included in the safety population.</population>
          <units>milisecond</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="7.2"/>
                    <measurement group_id="O2" value="131.7" spread="124.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in One Second (FEV1)</title>
        <description>The ratio of the average value of available data for mean from Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group</description>
        <time_frame>Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1)</title>
          <description>The ratio of the average value of available data for mean from Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>percentage of baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.46" lower_limit="68.9" upper_limit="139.2"/>
                    <measurement group_id="O2" value="99.42" lower_limit="80.3" upper_limit="165.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group</description>
        <time_frame>Before randomization, 0, 4, 8, 17, 26, 34, 43 and 52 weeks after randomization</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>The ratio of the average value of available data for Weeks 0, 4, 8, 17, 26, 34, 43 and 52 to the baseline for each treatment group</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>Percentage of baseline</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.62" lower_limit="76.9" upper_limit="157.3"/>
                    <measurement group_id="O2" value="99.13" lower_limit="75.3" upper_limit="163.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow(PEF)</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit)and daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow(PEF)</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>Liter/minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="34.9"/>
                    <measurement group_id="O2" value="7.3" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Peak Expiratory Flow (PEF)</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Evening Peak Expiratory Flow (PEF)</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>Liter/minute (L/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="34.0"/>
                    <measurement group_id="O2" value="7.9" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
        <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Night-time Awakening Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
          <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.4"/>
                    <measurement group_id="O2" value="-0.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
        <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Breathlessness Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
          <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.7"/>
                    <measurement group_id="O2" value="-0.2" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
        <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit) and daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Cough Due to Chronic Obstructive Pulmonary Disease (COPD) Symptoms</title>
          <description>There are 5 alternatives (scored 0 to 4, with 4 being the most severe condition). The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.8"/>
                    <measurement group_id="O2" value="-0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score</title>
        <description>The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.</description>
        <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Total Chronic Obstructive Pulmonary Disease (COPD) Symptom Score</title>
          <description>The Total COPD Symptom score is the sum of the measures night-time awakening, breathlessness and cough, ranges from 0 to 12 with 12 being the most severe. The change from Run-in period average to Treatment period average for each treatment group.</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.2"/>
                    <measurement group_id="O2" value="-0.4" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD Exacerbations Over the Treatment Period</title>
        <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment was presented here.</description>
        <time_frame>Daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD Exacerbations Over the Treatment Period</title>
          <description>A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as worsening in COPD symptoms requiring treatment with either a course of systemic steroid or hospitalisation. Number of COPD exacerbation during 52-week randomization treatment was presented here.</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>number of exacerbations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of SABA (Salbutamol) as Reliever Medication</title>
        <description>The change from Run-in period average to Treatment period average for each treatment group.</description>
        <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Use of SABA (Salbutamol) as Reliever Medication</title>
          <description>The change from Run-in period average to Treatment period average for each treatment group.</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>Times/Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.7"/>
                    <measurement group_id="O2" value="0.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St George’s Respiratory Questionnaire (SGRQ) Total Score</title>
        <description>SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). The change from Run-in period average to Treatment period average for each treatment group</description>
        <time_frame>Daily during run-in period (14 - 18 days before Randomisation visit ) and daily during 52-week randomization treatment</time_frame>
        <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - Formoterol</title>
            <description>Formoterol 9 μg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - Standard Treatment</title>
            <description>Standard COPD (JRS guideline and GOLD) treatment</description>
          </group>
        </group_list>
        <measure>
          <title>St George’s Respiratory Questionnaire (SGRQ) Total Score</title>
          <description>SGRQ total score shows the impact of COPD on patient's health status, and expressed as a percentage of impairment with scale from 0 (best health status) to 100 (worst possible status). A negative rate of decline shows decreasing SGRQ total score (or improved health) over time, while a positive value shows increasing score (or worsen health). The change from Run-in period average to Treatment period average for each treatment group</description>
          <population>All randomised subjects who received at least one dose of formoterol or standard COPD treatment for each treatment group respectively and for whom any efficacy data after randomisation were available were included in the efficacy population (Full Analysis Set: FAS).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="8.48"/>
                    <measurement group_id="O2" value="-0.57" spread="7.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Formoterol</title>
          <description>Formoterol 9 μg twice daily</description>
        </group>
        <group group_id="E2">
          <title>Standard Treatment</title>
          <description>Standard COPD (JRS guideline and GOLD) treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Venom Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Spinal Cord Injury Cervical</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Chest X-Ray Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Oesophageal Squamous Cell Carcinoma Stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Bone Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lacunar Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Loss Of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Brain Stem Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Spermatic Cord Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>SPERMATIC CORD DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Dermatitis Contact</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

